Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KU60648 |
Synonyms | |
Therapy Description |
KU60648 is a DNA protein kinase inhibitor, which may lead to impairment of double stranded break repair, thereby resulting in decreased cell viability (PMID: 28224663). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KU60648 | KU-0060648 | DNA_PK Inhibitor 9 | KU60648 is a DNA protein kinase inhibitor, which may lead to impairment of double stranded break repair, thereby resulting in decreased cell viability (PMID: 28224663). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MSH6 loss | colon cancer | no benefit | KU60648 | Preclinical - Cell culture | Actionable | In a preclinical study, MSH6 deficient colon cancer cells did not respond to treatment with KU60648 in culture (PMID: 28224663). | 28224663 |
MLH1 loss | colon cancer | sensitive | KU60648 | Preclinical - Cell culture | Actionable | In a preclinical study, MLH1 deficient colon cancer cell lines were sensitive to KU60648 in culture, demonstrating decreased cell viability and reduced colony formation (PMID: 28224663). | 28224663 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|